by Lance Smith | Jan 17, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Surge of Research Organizations Investing in Florence Shows New Wave of Site Leadership in Streamlining Study Operations ATLANTA – January 16, 2020 – (Newswire.com) Florence, an Atlanta-based clinical trial software company, today announces that it doubled...by Lance Smith | Jan 17, 2020 | Study Scavenger Clinical Trial Recruitment Platform
WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the Company has dosed the first cohort in its Phase 1 trial to...by Lance Smith | Jan 17, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Kala Pharmaceuticals has completed enrollment in the STRIDE 3 trial for KPI-121 0.25%, a treatment for temporary dry eye relief, according to a press release. The enrollment follows a previous new drug application rejection from the FDA, which said that efficacy data...by Lance Smith | Jan 17, 2020 | Study Scavenger Clinical Trial Recruitment Platform
OXFORD, UK / ACCESSWIRE / January 17, 2020 / IntraBio Inc, a late-stage biopharmaceutical company, is pleased to share that it has completed enrollment for its IB1001-201 Clinical Trial. IB1001-201 investigates N-Acetyl-L-Leucine (IB1001) for both the symptomatic, and...by Lance Smith | Jan 17, 2020 | Study Scavenger Clinical Trial Recruitment Platform
The House Energy and Commerce Subcommittee on Health held a hearing on cannabis with much of the focus on research, with the Drug Enforcement Administration revealing that it has a cultivation licensing proposal pending before the White House Office of Management and...by Lance Smith | Jan 16, 2020 | Study Scavenger Clinical Trial Recruitment Platform
CAMBRIDGE, Mass., Jan. 16, 2020 /PRNewswire/ — Neuroptika, a privately held biotechnology company focused on the development of novel regenerative treatments for ophthalmic diseases, today announced that the first patient was enrolled in a Phase 2 clinical trial...